Search International and National Patent Collections
|1. (WO2018199049) NOVEL DNMT INHIBITOR AS SOLID TUMOR THERAPEUTIC DRUG|
|Applicants:||OHARA PHARMACEUTICAL CO., LTD.
|Title:||NOVEL DNMT INHIBITOR AS SOLID TUMOR THERAPEUTIC DRUG|
[Problem] To provide, in place of injected agents (such as Vidaza (registered trademark) and Dacogen (registered trademark)) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.)